Literature DB >> 24790184

Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity.

Igor Klyubin1, Andrew J Nicoll, Azadeh Khalili-Shirazi, Michael Farmer, Stephanie Canning, Alexandra Mably, Jacqueline Linehan, Alexander Brown, Madeleine Wakeling, Sebastian Brandner, Dominic M Walsh, Michael J Rowan, John Collinge.   

Abstract

Alzheimer's disease (AD) is associated with pathological assembly states of amyloid-β protein (Aβ). Aβ-related synaptotoxicity can be blocked by anti-prion protein (PrP) antibodies, potentially allowing therapeutic targeting of this aspect of AD neuropathogenesis. Here, we show that intravascular administration of a high-affinity humanized anti-PrP antibody to rats can prevent the plasticity-disrupting effects induced by exposure to soluble AD brain extract. These results provide an in vivo proof of principle for such a therapeutic strategy.

Entities:  

Keywords:  Alzheimer's; drug discovery; immunotherapy; long-term potentiation; prion

Mesh：

Substances：

Year:  2014        PMID： 24790184      PMCID： PMC4004804          DOI： 10.1523/JNEUROSCI.3526-13.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN： 0270-6474            Impact factor:   6.167


  27 in total

Review 1.  The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions.

Authors:  Maxime Béland; Xavier Roucou
Journal:  J Neurochem       Date:  2012-03       Impact factor: 5.372

Review 2.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

Review 3.  A synaptic model of memory: long-term potentiation in the hippocampus.

Authors:  T V Bliss; G L Collingridge
Journal:  Nature       Date:  1993-01-07       Impact factor: 49.962

4.  The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein.

Authors:  Tiziana Sonati; Regina R Reimann; Jeppe Falsig; Pravas Kumar Baral; Tracy O'Connor; Simone Hornemann; Sine Yaganoglu; Bei Li; Uli S Herrmann; Barbara Wieland; Mridula Swayampakula; Muhammad Hafizur Rahman; Dipankar Das; Nat Kav; Roland Riek; Pawel P Liberski; Michael N G James; Adriano Aguzzi
Journal:  Nature       Date:  2013-07-31       Impact factor: 49.962

5.  Therapeutic effect of peripheral administration of an anti-prion protein antibody on mice infected with prions.

Authors:  Natsuo Ohsawa; Chang-Hyun Song; Akio Suzuki; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  Microbiol Immunol       Date:  2013-04       Impact factor: 1.955

6.  Cross-linking cellular prion protein triggers neuronal apoptosis in vivo.

Authors:  Laura Solforosi; Jose R Criado; Dorian B McGavern; Sebastian Wirz; Manuel Sánchez-Alavez; Shuei Sugama; Lorraine A DeGiorgio; Bruce T Volpe; Erika Wiseman; Gil Abalos; Eliezer Masliah; Donald Gilden; Michael B Oldstone; Bruno Conti; R Anthony Williamson
Journal:  Science       Date:  2004-01-29       Impact factor: 47.728

7.  A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.

Authors:  S Angal; D J King; M W Bodmer; A Turner; A D Lawson; G Roberts; B Pedley; J R Adair
Journal:  Mol Immunol       Date:  1993-01       Impact factor: 4.407

8.  PrP antibodies do not trigger mouse hippocampal neuron apoptosis.

Authors:  Peter-Christian Klöhn; Michael Farmer; Jacqueline M Linehan; Catherine O'Malley; Mar Fernandez de Marco; William Taylor; Mark Farrow; Azy Khalili-Shirazi; Sebastian Brandner; John Collinge
Journal:  Science       Date:  2012-01-06       Impact factor: 47.728

9.  Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.

Authors:  Juha Laurén; David A Gimbel; Haakon B Nygaard; John W Gilbert; Stephen M Strittmatter
Journal:  Nature       Date:  2009-02-26       Impact factor: 49.962

10.  The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes.

Authors:  Magdalini Polymenidou; Rita Moos; Mike Scott; Christina Sigurdson; Yong-Zhong Shi; Bill Yajima; Iva Hafner-Bratkovic; Roman Jerala; Simone Hornemann; Kurt Wuthrich; Anne Bellon; Martin Vey; Graciela Garen; Michael N G James; Nat Kav; Adriano Aguzzi
Journal:  PLoS One       Date:  2008-12-08       Impact factor: 3.240
View more
  36 in total

Review 1.  Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.

Authors:  Santiago V Salazar; Stephen M Strittmatter
Journal:  Biochem Biophys Res Commun       Date:  2016-09-14       Impact factor: 3.575

2.  Ginsenoside Rg1 and Acori Graminei Rhizoma Attenuates Neuron Cell Apoptosis by Promoting the Expression of miR-873-5p in Alzheimer's Disease.

Authors:  Ran Shi; Sishuo Zhang; Guangqing Cheng; Xiaoni Yang; Ningning Zhao; Chao Chen
Journal:  Neurochem Res       Date:  2018-06-20       Impact factor: 3.996

3.  Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease.

Authors:  Simon Mead; Matthew Burnell; Jessica Lowe; Andrew Thompson; Ana Lukic; Marie-Claire Porter; Christopher Carswell; Diego Kaski; Janna Kenny; Tze How Mok; Nina Bjurstrom; Edit Franko; Michele Gorham; Ronald Druyeh; Jonathan D F Wadsworth; Zane Jaunmuktane; Sebastian Brandner; Harpreet Hyare; Peter Rudge; A Sarah Walker; John Collinge
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

4.  Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease.

Authors:  Santiago V Salazar; Christopher Gallardo; Adam C Kaufman; Charlotte S Herber; Laura T Haas; Sophie Robinson; Jean C Manson; Michael K Lee; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

Review 5.  Prion neurotoxicity.

Authors:  Nhat T T Le; Bei Wu; David A Harris
Journal:  Brain Pathol       Date:  2019-01-17       Impact factor: 6.508

6.  Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.

Authors:  Erin Bove-Fenderson; Ryo Urano; John E Straub; David A Harris
Journal:  J Biol Chem       Date:  2017-08-23       Impact factor: 5.157

7.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

8.  Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.

Authors:  Erik C Gunther; Levi M Smith; Mikhail A Kostylev; Timothy O Cox; Adam C Kaufman; Suho Lee; Ewa Folta-Stogniew; George D Maynard; Ji Won Um; Massimiliano Stagi; Jacqueline K Heiss; Austin Stoner; Geoff P Noble; Hideyuki Takahashi; Laura T Haas; John S Schneekloth; Janie Merkel; Christopher Teran; Zahra K Naderi; Surachai Supattapone; Stephen M Strittmatter
Journal:  Cell Rep       Date:  2019-01-02       Impact factor: 9.423

9.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.

Authors:  Tomas Ondrejcak; Igor Klyubin; Grant T Corbett; Graham Fraser; Wei Hong; Alexandra J Mably; Matthew Gardener; Jayne Hammersley; Michael S Perkinton; Andrew Billinton; Dominic M Walsh; Michael J Rowan
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

Review 10.  Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.

Authors:  Levi M Smith; Stephen M Strittmatter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.